Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
Bank of America Corp DE Decreases Position in Ascendis Pharma A/S (NASDAQ:ASND)
08:54am, Tuesday, 21'st Apr 2020
Bank of America Corp DE lowered its position in Ascendis Pharma A/S (NASDAQ:ASND) by 25.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exch
Ascendis Pharma (ASND) Received its Third Buy in a Row
03:45pm, Monday, 20'th Apr 2020
After Merrill Lynch and Canaccord Genuity gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy, this time from
Ascendis Pharma (ASND) Received its Third Buy in a Row
03:45pm, Monday, 20'th Apr 2020
After Merrill Lynch and Canaccord Genuity gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink ASND;TAK
01:41pm, Monday, 20'th Apr 2020
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink SVB Leerink ASND TAK
Ascendis Pharma price target raised to $150 from $145 at JPMorgan ASND
01:04pm, Monday, 20'th Apr 2020
Ascendis Pharma price target raised to $150 from $145 at JPMorgan JPMorgan ASND
Ascendis Pharma price target raised to $219 from $199 at Oppenheimer ASND
01:02pm, Monday, 20'th Apr 2020
Ascendis Pharma price target raised to $219 from $199 at Oppenheimer Oppenheimer ASND
Ascendis Pharma price target raised to $170 from $166 at Canaccord ASND
12:03pm, Monday, 20'th Apr 2020
Ascendis Pharma price target raised to $170 from $166 at Canaccord Canaccord ASND
Ascendis Pharma price target raised to $149 from $139 at Credit Suisse ASND
12:02pm, Monday, 20'th Apr 2020
Ascendis Pharma price target raised to $149 from $139 at Credit Suisse Credit Suisse ASND
Ascendis Pharma price target raised to $201 from $185 at Cantor Fitzgerald ASND
11:29am, Monday, 20'th Apr 2020
Ascendis Pharma price target raised to $201 from $185 at Cantor Fitzgerald Cantor Fitzgerald ASND
Ascendis Pharma (ASND) Received its Third Buy in a Row
11:24am, Monday, 20'th Apr 2020
After Merrill Lynch and Canaccord Genuity gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy, this time from
Ascendis Pharma (ASND) Received its Third Buy in a Row
11:24am, Monday, 20'th Apr 2020
After Merrill Lynch and Canaccord Genuity gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another
Ascendis Pharma's TransCon PTH shows positive effect in adults with low parathyroid hormone
10:35am, Monday, 20'th Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) announces positive results from a Phase 2 clinical trial, PaTH Forward, evaluating TransCon PTH in adults with hypoparathyroidism (low levels for parathyroid hormone
Ascendis Pharma (ASND) Received its Third Buy in a Row
10:11am, Monday, 20'th Apr 2020
After Merrill Lynch and Oppenheimer gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy, this time from
Ascendis Pharma (ASND) Received its Third Buy in a Row
10:11am, Monday, 20'th Apr 2020
After Merrill Lynch and Oppenheimer gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy,
Ascendis Pharma A/S (NASDAQ:ASND) Rating Increased to Buy at BidaskClub
09:42am, Monday, 20'th Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Monday, BidAskClub reports. A number of other bro
